HCM
PGNX

Highbridge Capital Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Highbridge Capital Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-63,548
Closed -$402K – 1727
2016
Q3 		$402K Buy
+63,548
New +$384K 0.01% 882
2016
Q1 		– Sell
-78,134
Closed -$479K – 1944
2015
Q4 		$479K Buy
78,134
+29,705
+61% +$195K 0.01% 1007
2015
Q3 		$277K Buy
+48,429
New +$372K ﹤0.01% 1263
2015
Q1 		– Sell
-46,478
Closed -$351K – 1673
2014
Q4 		$351K Buy
+46,478
New +$278K ﹤0.01% 918
2014
Q2 		– Sell
-172,960
Closed -$708K – 1357
2014
Q1 		$708K Buy
+172,960
New +$885K 0.01% 629
2013
Q4 		– Sell
-266,719
Closed -$1.34M – 1419
2013
Q3 		$1.34M Buy
266,719
+189,284
+244% +$1.03M 0.01% 600
2013
Q2 		$346K Buy
+77,435
New +$347K ﹤0.01% 993

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
PFC
Phocas Financial Corp Alameda, California $637M AUM 39.08% 1-Year Est. Return

Highbridge Capital Management's PGNX Position: Q4 2016 in Review

Highbridge Capital Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2016, closing a stake of 63,548 shares — an estimated $402K sold.

Highbridge Capital Management first reported a position in PGNX in Q2 2013 and held it in 7 quarters. The position peaked at $1.34M in Q3 2013. 126 funds tracked by Wall St. Rank hold PGNX as of Q4 2016.

  • Highbridge Capital Management reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2016 after selling out during the quarter.
  • Highbridge Capital Management sold 63,548 Progenics Pharmaceuticals Inc shares in Q4 2016, an estimated $402K.
  • Highbridge Capital Management first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 7 quarters.
  • Highbridge Capital Management's Progenics Pharmaceuticals Inc position peaked at $1.34M in Q3 2013.
  • 126 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2016.

Based on Highbridge Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.